<DOC>
	<DOCNO>NCT00523978</DOCNO>
	<brief_summary>This study ( STOP AF ) prospective , randomize , control , multicenter , pivotal clinical investigation conduct 26 investigational site United States Canada . Subjects paroxysmal atrial fibrillation ( PAF ) refer ablative intervention efficacy failure one Study Atrial Fibrillation ( AF ) Drugs ( flecainide , propafenone sotalol ) randomize 2:1 cryoablation intervention ( Experimental Subjects , ES ) Study AF Drug ( Control Subjects , CS ) . Subjects follow 12 month schedule symptom-driven assessment detect recurrent atrial fibrillation mean periodic electrocardiogram , weekly schedule trans-telephonic monitoring , patient-initiated trans-telephonic monitoring , 24-hour Holter monitoring 6 12 month . The first 90 day study therapy initiate consider blanked period subject .</brief_summary>
	<brief_title>A Clinical Study Arctic Front Cryoablation Balloon Treatment Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>STOP AF ( PS-023 ) randomize , control study subject 18 75 year old refer ablative intervention fail one two ( three ) anti-arrhythmic drug use treatment AF ( flecainide , propafenone sotalol ) . Study subject randomize two arm : cryoablation ( treatment ) arm membrane-active antiarrhythmic drug ( control ) arm . A 90- day blank follow-up period , include reablation medication adjustment apply arm optimize therapy . All subject underwent follow-up assessment 1 , 3 , 6 , 9 12 month , weekly transtelephonic monitoring , 24-hour Holter monitoring CT/MRI pulmonary vein ( 6 12 month ) trial period . Control subject confirm chronic treatment failure permit crossover cryoablation trial . Acute procedural success define subject underwent cryoablation demonstrate electrical isolation ≥ 3 Pulmonary Veins ( PVs ) conclusion first protocol-defined cryoablation procedure use Arctic Front® Cardiac CryoAblation Catheter System . The primary effectiveness endpoint define acute procedural success freedom chronic treatment failure ( CTF ) experimental subject , freedom CTF control subject . Freedom ( CTF ) define group occurrence detectable AF non-blanked follow-up period , AF Intervention , use non-study AF drug time . The co-primary safety outcome measure Cryoablation Procedure Events ( CPEs ) cryoablated subject Major Atrial Fibrillation Events ( MAFEs ) group . CPEs device- procedure-related serious adverse event . Other safety assessment make course STOP AF trial specific pulmonary vein stenosis ( PVS ) phrenic nerve injury .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<mesh_term>Propafenone</mesh_term>
	<criteria>Documented Paroxysmal Atrial Fibrillation ( PAF ) : PAF diagnosis , 2 episode PAF within last 2 month , least 1 episode PAF must document Age 1875 Documented Effectiveness Failure one ( 1 ) AF drug Willing randomize either group full 12 month followup Able follow standardize AF drug protocol Any cardioversion within 3 month 2 within 2 year Amiodarone within 6 month LA size &gt; 5.0cm Previous LA ablation/surgery , structural heart disease , heart failure class III IV Hypertrophic cardiomyopathy , Mitral prosthesis Unstable angina , uncontrolled hyperthyroidism Stroke TIA within 6 month , MI within 2 month , cardiac surgery within 3 month Thrombocytosis , thrombocytopenia Any condition contraindicate chronic anticoagulation EF &lt; 40 % Pregnancy Life expectancy &lt; 1year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>